CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
2.420
+0.110 (4.76%)
At close: Oct 5, 2026, 4:00 PM EDT
2.450
+0.030 (1.24%)
Pre-market: Oct 6, 2026, 5:38 AM EDT
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
42.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Werewolf Therapeutics | 21.00M |
| Veru Inc. | 16.89M |
| Metagenomi Therapeutics | 13.56M |
| CervoMed | 331.30K |
| Impact BioMedical | 35.00K |
CVM News
- 20 days ago - CEL-SCI to deliver keynote at Otorhinolaryngology 2026 - TheFly
- 20 days ago - CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology - Business Wire
- 7 weeks ago - CEL-SCI reports Q3 EPS (47c) vs ($1.36) last year - TheFly
- 7 weeks ago - CEL-SCI Reports Fiscal Third Quarter 2026 Results - Business Wire
- 2 months ago - CEL-SCI announces publication of study supporting multikine biomarker strategy - TheFly
- 2 months ago - CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Business Wire
- 2 months ago - CEL-SCI announces manuscript on Phase 3 study to be published in Oral Oncology - TheFly
- 2 months ago - Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business Wire